国药一致(000028) - 2025 Q3 - 季度业绩

Financial Performance - For the first three quarters of 2025, the total operating revenue was CNY 55.12 billion, a decrease of 2.38% year-on-year [4]. - The net profit attributable to shareholders was CNY 9.57 billion, down 10.18% compared to the previous year, with basic earnings per share decreasing by 9.95% [9]. - In Q3 2025, the total operating revenue was CNY 18.33 billion, a decline of 1.89% year-on-year, while the net profit attributable to shareholders was CNY 2.91 billion, down 9.58% [9]. - The distribution segment achieved operating revenue of CNY 40.59 billion, a decrease of 0.59% year-on-year, with net profit of CNY 0.72 billion, down 7.32% [9]. - The retail segment (Guoda Pharmacy) generated operating revenue of CNY 15.23 billion, a decline of 7.14%, but net profit increased by 133.91% to CNY 0.13 billion [9]. Asset and Equity Growth - The total assets increased by 6.31% year-on-year to CNY 505.59 billion [5]. - The equity attributable to shareholders rose by 4.30% to CNY 184.30 billion [5]. Strategic Focus - The company aims to focus on "increasing revenue, reducing costs, and improving efficiency" while accelerating digital transformation and organizational change [10]. - The company plans to continue optimizing its business structure and enhancing risk resistance capabilities amid a complex external environment [10]. Return on Investment - The weighted average return on net assets decreased by 0.70 percentage points to 5.29% [5].